DekaBank Deutsche Girozentrale Sells 69,500 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

DekaBank Deutsche Girozentrale reduced its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 14.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 411,897 shares of the company's stock after selling 69,500 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.17% of BioNTech worth $36,620,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. FMR LLC increased its position in shares of BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the period. Bank of New York Mellon Corp raised its stake in shares of BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after buying an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of BioNTech during the 4th quarter worth about $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Finally, Capital International Investors raised its position in BioNTech by 38.6% in the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after purchasing an additional 394,434 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BNTX has been the topic of several analyst reports. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Morgan Stanley set a $133.00 price target on BioNTech and gave the company an "overweight" rating in a research report on Thursday. HC Wainwright restated a "buy" rating and issued a $138.00 target price on shares of BioNTech in a research note on Wednesday, June 25th. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, Citigroup restated a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and an average target price of $137.91.

BioNTech Trading Down 0.9%

NASDAQ:BNTX traded down $1.03 on Friday, hitting $112.89. 521,908 shares of the stock were exchanged, compared to its average volume of 943,543. The stock has a market capitalization of $27.14 billion, a price-to-earnings ratio of -33.20 and a beta of 1.29. BioNTech SE Sponsored ADR has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The company's 50-day moving average price is $103.56 and its 200 day moving average price is $106.76.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.